VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

Phase 2

Completed

• Conditions: Mantle Cell Lymphoma

• Registration Number: NCT00063713
• Lead Sponsor: Millennium Pharmaceuticals, Inc.

Brief Summary

The purpose of this study is to find out whether treatment with VELCADE will increase the time it takes for lymphoma to get worse.

Detailed Description

VELCADE is approved in multiple myeloma for patients who have received two prior therapies and their disease came back or got worse while on their second therapy. VELCADE is currently being studied in other types of cancers.

Study Timeline

• Study Start: 2003-06
• Study First Submitted: 2003-07-02
• Study First Submitted QC: 2003-07-03
• Study First Posted: 2003-07-04
• Primary Completion: 2005-12
• Status Verified: 2008-02
• Last Update Submitted: 2008-02-07
• Last Update Posted: 2008-02-11

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 152

Inclusion Criteria

Not provided

Exclusion Criteria

Not provided

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Trial Locations

Locations (34)

University of Alabama; 🇺🇸 Birmingham, Alabama, United States

Alta Bates Medical Center; 🇺🇸 Berkeley, California, United States

City of Hope Comprehensive Cancer Center; 🇺🇸 Duarte, California, United States

Loma Linda Cancer Research Institute; 🇺🇸 Loma Linda, California, United States

UCLA School of Medicine; 🇺🇸 Los Angeles, California, United States

Stanford University; 🇺🇸 Palo Alto, California, United States

University of Colorado Cancer; 🇺🇸 Denver, Colorado, United States

Georgetown University Medical Center Lombardi Cancer Center; 🇺🇸 Washington, District of Columbia, United States

H. Lee Moffitt Cancer Center & Research Institute; 🇺🇸 Tampa, Florida, United States

The Emory Clinic; 🇺🇸 Atlanta, Georgia, United States

Scroll for more (24 remaining)